PROCEPT BioRobotics Stock
Medical device company
Sign up today and learn more about PROCEPT BioRobotics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About PROCEPT BioRobotics Stock
PROCEPT BioRobotics is a clinical-stage medical device company based in Silicon Valley. The Company has developed a disruptive surgical product for transurethral resection of prostate tissue – The AquaBeam® – and other treatment and diagnostic applications. The AquaBeam is a personalized image-guided tissue removal system, which utilizes proprietary heat-free high-velocity waterjet technology to resect and remove a predetermined volume of tissue with precise and automated incisions conforming to the shape of the prostate.
Investors
Novo Holdings
Perceptive Advisors
Zymergen, Freenome, Omada Health, Crossover Health, Twin Health, Emulate, PROCEPT BioRobotics, AEGEA Medical, Saama
Viking Global Investors
Impossible Foods, Moderna Therapeutics, Apeel Sciences, Adaptive Biotechnologies, Arctic Wolf, Talkdesk, Druva, Color, Clip, Iterable
Funding History
| October 2013 | $6.0M |
|---|---|
| August 2014 | $2.0M |
| July 2015 | $7.7M |
| July 2015 | $42.0M |
| June 2017 | $25.0M |
| February 2018 | $118M |
Management
Co-Founder & Chief Executive Officer
Nikolai Aljuri
Chief Financial Officer
Kevin Waters
Press
Business Wire - Nov, 6 2019
PROCEPT BioRobotics’ AquaBeam® Robotic System Receives CMS Approval for Transitional Pass-Through Payment Statusmassdevice - May, 20 2019
Procept BioRobotics touts slew of Aquablation therapy study resultsmassdevice - Mar, 26 2019
Hydrocision, Procept BioRobotics ink licensing dealEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
